{"id":70736,"date":"2026-07-27T21:34:16","date_gmt":"2026-07-27T13:34:16","guid":{"rendered":"https:\/\/flcube.com\/?p=70736"},"modified":"2026-07-27T21:34:17","modified_gmt":"2026-07-27T13:34:17","slug":"sanofi-halts-amlitelimab-development-in-atopic-dermatitis-despite-positive-long-term-safety-data","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70736","title":{"rendered":"Sanofi Halts Amlitelimab Development in Atopic Dermatitis Despite Positive Long-Term Safety Data"},"content":{"rendered":"\n

Sanofi S.A.<\/strong> (NASDAQ: SNY<\/a>) announced the discontinuation of clinical development<\/strong> of amlitelimab<\/strong>, an OX40-ligand monoclonal antibody<\/strong>, in moderate-to-severe atopic dermatitis (AD)<\/strong>. The decision not to pursue global regulatory submissions was made as part of an ongoing strategic pipeline assessment, with Sanofi determining that the totality of efficacy and safety evidence does not support further development in this indication.<\/p>\n\n\n\n

Pipeline Decision Summary<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Sanofi S.A. (NASDAQ: SNY)<\/td><\/tr>
Drug Candidate<\/strong><\/td>Amlitelimab (OX40-ligand monoclonal antibody)<\/td><\/tr>
Indication<\/strong><\/td>Moderate-to-severe atopic dermatitis (AD)<\/td><\/tr>
Decision Type<\/strong><\/td>Clinical development discontinuation<\/td><\/tr>
Regulatory Status<\/strong><\/td>No global regulatory submissions planned<\/td><\/tr>
Rationale<\/strong><\/td>Insufficient differentiation from current standard of care<\/td><\/tr>
Affected Study<\/strong><\/td>ESTUARY Phase 3 long-term extension (NCT06407934)<\/td><\/tr>
Patient Population<\/strong><\/td>Patients aged 12 years and older with moderate-to-severe AD<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Data Assessment<\/h2>\n\n\n\n